Premium
Role of adjuvant chemotherapy in male breast cancer
Author(s) -
Patel Helen Z.,
Buzdar Aman U.,
Hortobagyi Gabriel N.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19891015)64:8<1583::aid-cncr2820640804>3.0.co;2-q
Subject(s) - medicine , cyclophosphamide , breast cancer , fluorouracil , adjuvant , chemotherapy , methotrexate , adjuvant therapy , doxorubicin , oncology , cancer , population , surgery , stage (stratigraphy) , environmental health , paleontology , biology
Eleven consecutive male patients with operable Stage II (n = 7) or III (n = 4) breast cancer were treated with adjuvant chemotherapy after local therapy. Adjuvant therapy consisted of 5‐fluorouracil, doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) in ten patients and cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) in one patient. At a median follow‐up time of 52 months, four patients experienced a relapse and seven patients were disease‐free. Of those with recurrent disease, one patient died of metastatic breast cancer. These limited data suggest that adjuvant therapy reduced the risk of recurrence and favorably influenced the survival in this patient population. Adjuvant therapy should be considered in male patients with primary breast cancer.